logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: Drugs
Load new posts () and activity
Like Reblog Comment
text 2018-11-16 09:46
Methotrexate Drugs Market

Methotrexate MTX, formerly known as amethopterin, is a chemotherapy agent and immune system suppressant.[1] It is used to treat cancer, autoimmune diseases, ectopic pregnancy, and for medical abortions.
In 2017, the global Methotrexate Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Methotrexate Drugs market based on company, product type, application and key regions.

This report studies the global market size of Methotrexate Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Methotrexate Drugs in these regions.
This research report categorizes the global Methotrexate Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

The various contributors involved in the value chain of Methotrexate Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Methotrexate Drugs include
Silvergate Pharmaceuticals

Market Size Split by Type
2.5mg/ml
2mg/ml
Market Size Split by Application
Cancer
Autoimmune Diseases
Other

Market size split by Region
North America
United States
Canada
Mexico
AsiaPacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Methotrexate Drugs market size value & volume by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Methotrexate Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industryspecific challenges and risks.
Focuses on the key global Methotrexate Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Methotrexate Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Methotrexate Drugs submarkets, with respect to key regions along with their respective key countries.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Methotrexate Drugs are as follows:
History Year: 20132017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value million US$ and volume K Units. Both topdown and bottomup approaches have been used to estimate and validate the market size of Methotrexate Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Source: www.qandqmarketresearch.com
Like Reblog Comment
text 2018-11-16 09:21
Dasatinib Drugs Market

Dasatinib, sold under the brand name Sprycel, is a chemotherapy medication used to treat certain cases of chronic myelogenous leukemia CML and acute lymphoblastic leukemia ALL.
In 2017, the global Dasatinib Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Dasatinib Drugs market based on company, product type, application and key regions.

This report studies the global market size of Dasatinib Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Dasatinib Drugs in these regions.
This research report categorizes the global Dasatinib Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

The various contributors involved in the value chain of Dasatinib Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Dasatinib Drugs include
BristolMyers Squibb
LUCIUS Pharma

Market Size Split by Type
20mg
50mg
70mg
Market Size Split by Application
CML
ALL

Market size split by Region
North America
United States
Canada
Mexico
AsiaPacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Dasatinib Drugs market size value & volume by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Dasatinib Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industryspecific challenges and risks.
Focuses on the key global Dasatinib Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Dasatinib Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Dasatinib Drugs submarkets, with respect to key regions along with their respective key countries.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Dasatinib Drugs are as follows:
History Year: 20132017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value million US$ and volume K Units. Both topdown and bottomup approaches have been used to estimate and validate the market size of Dasatinib Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Source: www.qandqmarketresearch.com
Like Reblog Comment
text 2018-11-16 09:14
Ponatinib Drugs Market

Ponatinib Drugs is an oral drug developed by ARIAD Pharmaceuticalsfor the treatment of chronic myeloid leukemia CML and Philadelphia chromosome–positive Ph+ acute lymphoblastic leukemiaALL. 
In 2017, the global Ponatinib Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Ponatinib Drugs market based on company, product type, application and key regions.

This report studies the global market size of Ponatinib Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Ponatinib Drugs in these regions.
This research report categorizes the global Ponatinib Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

The various contributors involved in the value chain of Ponatinib Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Ponatinib Drugs include
ARIAD Pharmaceuticals

Market Size Split by Type
45mg
15mg
Market Size Split by Application
CML
ALL

Market size split by Region
North America
United States
Canada
Mexico
AsiaPacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Ponatinib Drugs market size value & volume by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Ponatinib Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industryspecific challenges and risks.
Focuses on the key global Ponatinib Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Ponatinib Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Ponatinib Drugs submarkets, with respect to key regions along with their respective key countries.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Ponatinib Drugs are as follows:
History Year: 20132017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value million US$ and volume K Units. Both topdown and bottomup approaches have been used to estimate and validate the market size of Ponatinib Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Source: www.qandqmarketresearch.com
Like Reblog Comment
text 2018-11-05 14:42
Contraceptives Drugs And Devices Market provides an in-depth insight of Sales and Trends Forecast to 2026

Contraceptive drugs and devices that aid to control birth rate and unintended pregnancies are subject to unique regulatory challenges across different countries. For instance, contraceptive drugs and devices face reimbursement challenges in the U.S., while contraceptive pills face advertising restrictions in India. Owing to this, contraceptives preference greatly various across countries. Statistics revealed by the United Nations in 2015, highlight this trends, with a particular contraceptive accounting for over 50% share across 45 countries considered in the study. Sterilization is a dominant contraceptive method in regions such as Asia, North America, and Latin America as per the study. Intra-uterine devices (IUDs), vaginal rings, injectables, implants, combined oral contraceptives, and patches are some of the more advanced contraceptive methods available in the market. Introduction of new male contraceptive products with high success rate are projected to shape the course of growth of the market in the near future.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/365

Favorable reimbursement scenario in the U.S. to propel uptake of contraceptives

The affordability and accessibility of products to the U.S. citizens will be affected due to the new policies of President Trump on the Affordable Care Act. However, insurance coverage of health and reproductive products were allowed to be continued without any co-pays, co-insurance or deductibles by the State. Furthermore, this new policy would also cover all medically essential abortion services for the U.S. population. This is a much anticipated relief for the general population in the U.S., as around 45% of all pregnancies reported are unintended (CDC, 2009-2013 study data).

High preference for modern contraceptive methods in developed regions

As per results of a detailed study by the United Nation in 2015, 9 out of 10 married or in-union women opt for modern contraceptive methods. Use of IUD in the U.S. women population has resulted in decrease in the rate of unintended pregnancies from 51% (2006–2010) to 45% (2009–2013) as per the CDC’s National Survey of Family Growth. Furthermore, higher success rate and availability of reimbursement is encouraging women to opt for these methods over contraceptive pills. With increasing consumer awareness and rising accessibility to modern contraceptives methods, demand for these products is expected to increase in emerging economies such as India, China, and Brazil during the forecast period. Gynecologists and sexologists are recommending use of long-acting reversible contraceptives for couples who do not intend to have a child in near future, owing to their low side-effects and high effectiveness as compared to conventional contraceptives such as oral hormonal pills.

Factors impacting the contraceptive drugs and devices market in different regions:

Implementation of the stringent two-child policy in China since 2016, is a major factor driving demand for contraceptives in the country

Societal stigma impacting the demand for contraceptives negatively in Asia and Africa

Government programs encouraging the use of selected contraceptives affecting the market for other products (Indian government provides incentives for sterilization and distributes free condoms, while the U.S. Affordable Care Act emphasizes on complete insurance coverage for long-acting reversible contraceptives (LARC)

 

The global contraceptive drugs and devices market was valued at US$ 18,273.2 million in 2015 and is expected to expand at a CAGR of 7.8% during the forecast period (2016 – 2024).

Click To Reading More On Contraceptives Drugs And Devices Market

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Like Reblog Comment
text 2018-10-31 05:20
Diabetes Drugs Market Augmented Expansion to be Registered by 2024

The research report on the global market for diabetes drugs analyzes the present and future market scenario of the worldwide market. The positive regulatory for introduction of new drugs, increase in public and private funding for diabetes medicines, increasing commonness of diabetes has rev-up the growth of the global market for diabetes drugs. Rapid rise in elderly population around the world and increasing incidence as well as commonness of diabetes such as Type 1 diabetes and Type 2 diabetes are following aspects likely to increase the growth of global market for Diabetes drugs over the period of forecast.

Diabetes Drugs Market: Segmental Analysis & Regional Overview

The research study categorizes the global market for diabetes drugs into disease type, therapy, channel of distribution, and region.On the basis of disease type, this report segregate the global diabetes drugs market intoImpaired Glucose Tolerance and Impaired Fasting Glycaemia, Type 1 Diabetes, Gestational Diabetes, and Type 2 Diabetes. Based on channel of distribution, the study categorizes diabetes drugs market into online pharmacies, hospital pharmacies and Retail Pharmacies. According to therapy, the research study divides the international diabetes drugs market into Sodium glucose co-transporter 2 (SGLT2) inhibitors, Glucagon-like peptide-1 (GLP-1) agonist, Insulin, and others, Dipeptidyl-peptidase-4 (DPP-4) inhibitors.

 Request For Report Sample: https://www.researchreportinsights.com/report/upsample/120124589/Diabetes-Drugs-Market

Additionally, the Insulin lead the global market on the basis of revenue share in 2016. Due to increasing demand and need for the insulin, subsequently the price is high. Insulin is anticipated to dominate the diabetes drugs market in the assessment period. Sodium glucose co-transporter 2 is expected to grow over the period of assessment owing to exclusivity and patents. The other drug class are expected to rise throughout the period of forecast from 2017 to 2025. On the basis of region, the report bifurcates the worldwide market for diabetes drugs market into Asia Pacific, North America, the Middle East & Africa, Europe and Latin America. The report also presents market attractiveness index for report readers to make them understand the competitive landscape of the diabetes drugs market around the world. This section of the report showcase the regulations and polices along with the key findings. The report provide market value estimates by each region.

Request For Report TOC: https://www.researchreportinsights.com/report/TOC/120124589/Diabetes-Drugs-Market

Diabetes Drugs Market: Key Players Insights

The final portion of the research report offers a ‘dashboard view’ to its clients, enabling them to get a close insights of the competitive scenario of the worldwide diabetes drugs market. This section of chapter profiles key companies operating in the diabetes drugs market. The research report profiles prominent companies on the basis of various aspects such as financial overview, product portfolios, SWOT analysis, key strategies, as well as current development in the diabetes drugs market, across the globe. Some of the prominent companies featured in the report are as Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Eli Lilly and Company,Merck & Co., Inc.,Johnson & Johnson,Novartis AG,Bayer AG,BoehringerIngelheim GmbH, and Sanofi.

Report Analysis: https://www.researchreportinsights.com/report/upcomming/120124589/Diabetes-Drugs-Market

More posts
Your Dashboard view:
Need help?